Objective. To examine the association between frequent gouty arthritis and the presence of absolute/ relative contraindications to gout therapies, and health-care expenditure associated with frequent gouty arthritis.
Introduction
According to a recent analysis of the National Health and Nutrition Examination Survey data, about 8.3 million adults in the USA are affected by gout [1] . Gouty arthritis affects more men than women, with men 34 times more at risk for gout than women [2] . Risk of gout is also impacted by age and race, with the incidence among black men being about twice that of white men (3.1 vs 1.8 per 1000 person-years) [3] . Gout prevalence in the USA has increased in recent years, especially among the elderly [2, 4, 5] . The biggest risk factor for developing gouty arthritis is hyperuricaemia, or elevated serum urate concentration, which may be the result of either increased production of urate or decreased excretion of urate, and is commonly associated with decreased kidney function. Other associated risk factors include overweight/obesity, excessive alcohol consumption, hypertension and hypercholesterolaemia.
Current treatment options for the management of gouty arthritis are somewhat limited [68] . Treatment options for acute gouty arthritis include use of NSAIDs, colchicine and corticosteroids. Urate lowering therapies (i.e. allopurinol, febuxostat and probenecid) are used to reduce serum urate, and thus to reduce the risk of future gouty arthritis attacks. Gouty arthritis is associated with a high comorbidity burden, which may impact treatment options. Certain comorbidities, and/or treatments for those comorbidities, may contraindicate the use of medications used to treat gouty arthritis, or may be relative contraindications due to drugdrug interactions, drugdisease interactions or the need for dose limitations to help ensure medication safety [8] . For example, colchicine is contraindicated in patients with chronic kidney disease (CKD) or hepatic impairment who are treated with P-glycoprotein inhibitors or strong cytochrome p450 3A4 inhibitors [9] . In such a setting, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses [9, 10] . Similarly, NSAID use is relatively contraindicated in patients with heart failure due to the risk of exacerbation related to fluid retention and oedema [11, 12] .
Elderly patients with gouty arthritis have higher allcause health-care costs than comparable patients without gouty arthritis [13] . Among working-aged persons, claimbased studies have shown significantly higher annual total (direct + indirect) costs for employees with gouty arthritis as compared with patients who do not have gouty arthritis [14] . Disease severity (as defined by gouty arthritis attack frequency) has also been associated with higher rates of comorbid conditions, use of urgent care and outpatient visits, and incremental health-care costs [15] .
Patients with frequent gouty arthritis attacks are a challenge from a disease management perspective, and little information is available regarding gouty arthritis medication contraindication rates and associated gout-specific and total health-care costs among patients with frequent gouty arthritis attacks in a usual-care setting. The objectives of this study were to examine the association between frequent gouty arthritis (53 vs <3 attacks per year) and the presence of absolute and relative contraindications to gout therapies, as well as health-care expenditures associated with frequent gouty arthritis.
Methods

Study population
Thompson-Reuters commercial and Medicare MarketScan data, which contain medical (inpatient and outpatient) and pharmacy claims for patients across the USA, were used to identify patients eligible for this retrospective study. Patients aged 518 years with gouty arthritis were identified for study inclusion. Gouty arthritis was defined as the presence of 1 or more medical claims with an ICD-9-CM code associated with gout (274.xx) or at least one prescription claim for specific medications used in the management of gout (allopurinol, febuxostat, probenecid or colchicine) between 1 July 2005 and 30 June 2010. The date of the first diagnosis or prescription claim specific to gout was considered the study index date. Patients were required to have continuous medical and prescription benefit eligibility for at least 12 months preceding and following the index date. This study was approved by the Colorado Multiple Institutional Review Board at the University of Colorado Anschutz Medical Campus.
Gouty arthritis attack identification
A claims-based algorithm to identify gouty arthritis attacks was adapted from previous algorithms for use in this study [16, 17] . Attacks were defined through a claims history meeting one of the following four criteria: (i) a hospital admission or an emergency department visit with gout (ICD-9 274.xx) as a primary diagnosis; (ii) an outpatient visit with gout as a primary or secondary diagnosis followed by one of the following within 7 days: one or more medications used for the treatment of a gouty arthritis attack (NSAIDs, oral or injectable colchicine, oral or injectable corticosteroids, or adrenocorticotropic hormone), or medical follow-up (defined as IA aspiration and/or injection or microscopic examination of specimen from musculoskeletal system/joint fluid; see supplementary data Appendix 1, available at Rheumatology Online, for diagnostic codes); (iii) a hospital admission or an emergency department visit with joint pain (ICD-9 719.4x) as a primary diagnosis or an outpatient visit with joint pain as a primary or secondary diagnosis followed by a prescription drug claim for colchicine within 7 days; or (iv) a hospital admission or an emergency department visit or an outpatient visit with acute gouty arthritis (ICD-9 274.01) as a primary or secondary diagnosis subsequent to October 2009. Finally, separate successive attacks were required to occur at least 14 days apart (i.e. a 14-day gap from the start of the first attack until a subsequent attack).
Patients were stratified by disease severity based on frequency of gouty arthritis attacks as infrequent gout (<3 attacks per year) or frequent gout (53 attacks per year) using the year post-index date as the timeframe, consistent with methodology that has been used in previously published studies [15] . Infrequent gout patients were matched to those with frequent gout by age, gender and US geographical region, using a 2:1 ratio to create comparison groups with similar basic demographic characteristics. Other demographic variables included type of payer, the index year of gout diagnosis, number of patients in the health plan and number of enrolment months.
Comorbidities
Patient comorbidities were identified by the corresponding ICD-9-CM codes from medical claims in the 12 months after the index diagnosis. These included AS, cerebrovascular disease, CKD, chronic liver disease, [19] that are cited as warnings or cautions that threaten patient safety), drugdrug or drugdisease interactions that are considered major but not absolutely contraindicated, or drugdrug or drugdisease interactions where dose limitations are recommended to help ensure medication safety. These were identified using Food and Drug Administration product labelling for colchicine and febuxostat and were identified using Thomson Reuters Micromedex 2.0 [18] for NSAIDs, corticosteroids, allopurinol and probenecid (supplementary data Appendix 2, available at Rheumatology Online). The frequencies of relative contraindications were determined. The prevalence of using a drug known to cause gout (thiazide or loop diuretics, ciclosporin, niacin, levodopa, tacrolimus, teriparatide) was also determined. (iii) Health-care resource utilization was assessed using medical and pharmacy claims and calculated for the 1-year period post-index date. This included the number of outpatient visits, emergency department visits and hospitalizations, associated diagnostic testing (including laboratory and radiology), medications and length of hospitalizations (both all-cause and gout-specific). (iv) Corresponding total all-cause and gout-related health-care costs were calculated for the 1-year period post-index date, classified as total costs, medical-only costs and pharmacy-only costs.
Explanatory variables
Based on availability, theoretical and clinical judgements, the following explanatory variables were chosen:
(i) specific chronic conditions (yes/no) such as hypertension, ischaemic heart disease, heart failure, osteoporosis and CKD; (ii) comorbidity burden measured by chronic conditions index (number of chronic conditions excluding gout as well as the conditions listed above); (iii) industryspecific dummy variables; (iv) insurance coverage; (v) geographical region and (vi) age broken down into 10-year age intervals: 1834, 3544, 4554, 5564, 6474, 7584, 85 and older.
Statistical analysis
Resource use was evaluated overall, by gouty arthritis attack frequency and for patients with comorbidities vs those without. Gout-related costs were identified by the total amount corresponding to medical and pharmacy claims with specified diagnostic and/or procedural codes found in supplementary data Appendix 1, available at Rheumatology Online. For continuous variables, including costs, means, medians and S.D. were calculated for descriptive analyses, whereas frequencies were calculated for categorical variables. The means and medians associated with the frequency of yearly gouty arthritis attacks stratified by selected demographic and clinical characteristics were calculated. Bivariate analyses of continuous variables were conducted using t-tests or analysis of variance (ANOVA). Categorical variables were significance tested using the 2 test. Negative binomial modelling, a robust alternate to
Poisson regression, was used to estimate adjusted differences between patients with infrequent vs frequent attacks for all count-based outcome variables in the study, such as inpatient, outpatient and emergency department visits, as well inpatient length of stay. Negative binomial models were used because Poisson regression assumes the response variable has a Poisson distribution, with its mean equal to its variance [20] . However, in many cases, the observed variance is greater than the mean, which results in dispersion and non-robust estimates; negative binomial regression addresses this problem and is a robust alternative to analyse count data [21] . The adjusted incident rate ratios (IRRs) were reported for each regression. Adjusted analysis of cost data (all-cause and gout-related medical, pharmacy and total costs) was performed using logarithmic transformation of cost data and generalized linear models with a gamma distribution. For both negative binomial regression and generalized linear models, the following variables were included in the models: age; chronic condition index [22, 23] ; presence of common comorbidities including hypertension, ischaemic heart disease, heart failure, OA, CKD (including hypertensive and diabetic CKD); industry of employment (oil and gas extraction/ mining, manufacturing/durable goods, manufacturing/ non-durable goods, transportation/communications/utilities, retail trade, finance/insurance/real estate, services); type of health insurance plan (commercial or Medicare) and US geographical region (northeast, north central, south, west). All study analyses were conducted using SAS version 9. Table 1 . Mean patient age was 58 years, and 69% were men; 71% were covered by commercial health plans and 29% were participating in Medicare. The most common industries of subject employment were manufacturing (31%) and transportation (13%). Among all eligible subjects with gouty arthritis, 3% of subjects had three or more attacks per year. Compared with those with infrequent gout, those with frequent gout were more likely to be male (77.3% vs 69.2%, P < 0.0001). Demographic characteristics of the matched study cohort are included in Table 2 . Demographic characteristics for the matched cohort (n = 15 669) were similar to the entire study cohort, except that a greater proportion of subjects were male (77.3%). The prevalence rates of selected comorbidities for the matched study cohort are also included in Table 2 . As compared with patients with infrequent gout, those with frequent gout had significantly higher rates of CKD (including hypertensive and diabetic CKD), hypertension, dyslipidaemia, ischaemic heart disease, heart failure and arthritis (rheumatoid and OA), but not diabetes. Mean number of attacks per year was 0.51 for subjects with infrequent gout and 3.46 for those with frequent gout (Table 3) .
The proportion of gouty arthritis patients with absolute and/or relative contraindications to gouty arthritis treatment, stratified by yearly gouty arthritis attack frequency, is shown in Table 4 . Almost 91.5% of patients with frequent gout had absolute and/or relative contraindications to NSAID therapy, compared with 78.7% of patients with infrequent gout (P < 0.0001). Similarly, as compared with patients with infrequent gout, those with frequent gout were more likely to have absolute and/or relative contraindications to treatment with corticosteroids (96.4% vs 87.3%, P < 0.0001), allopurinol (51.0% vs 41.2%, P < 0.0001) and probenecid (13.4% vs 9.4%, P < 0.0001). There was no association between prevalence of absolute and/or relative contraindications to colchicine therapy and yearly gout attack frequency. Patients with frequent gout were more likely than those with infrequent gout to be prescribed a diuretic, which are known to cause or worsen gout.
The mean number of all-cause outpatient visits were 23.9 and 17.3 for patients with frequent gout vs infrequent gout (P < 0.001), and the mean number of gout-related outpatient visits were also higher among those with 
25).
A comparison of unadjusted health-care costs and adjusted differences by cost category for patients with frequent vs infrequent gout is shown in Table 6 . These costs were calculated for the 1-year period post-index gout diagnosis. Gout-related total medical costs were higher among patients with frequent gout. Compared with patients with infrequent gout, those with frequent gout had total adjusted annual medical costs that were $369 (95% CI: $1159, $420) lower and total annual prescription costs that were $65 (95% CI: $280, $150) lower, but these differences were not significant. Gout-related medical and prescription costs, in 2011 dollars and adjusted for covariates, were $559 (95% CI: $471, 647) and $23 (95% CI: $18, $29) higher, respectively, for patients with frequent gout.
Total all-cause health-care costs were calculated for the 1-year period post-index gout diagnosis. For patients with comorbidities and frequent gout, the costs were almost double than those incurred by patients without comorbidities and infrequent gout ($12 121 vs $6349). Among patients without comorbidities, those with frequent gout incurred total gout-related health-care costs that were more than double those incurred by patients with infrequent gout ($552 vs $220, P < 0.0001). Among those with comorbidities, this difference was even greater, as those with frequent gout averaged $942 in total gout-related health-care costs compared with $208 for those with infrequent gout (P < 0.0001). Results are given as n (%). a P values represent comparison of unadjusted costs using t-tests. Adjusted analysis was performed using negative binomial modelling adjusted for age; chronic condition index; presence of common comorbidities including hypertension, ischaemic heart disease, heart failure, OA, CKD (including hypertensive and diabetic CKD); industry of employment; type of health insurance plan and US geographical region. LOS: length of stay.
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Discussion
Overall, 45.2% of our study population had one or more gouty arthritis attacks per year, and 3% of subjects had three or more attacks per year (frequent gouty arthritis).
A comparison of patients with frequent gout to those with infrequent gout found that those with frequent gout had significantly higher rates of most comorbidities evaluated. These patients are also more difficult to treat, as they are more likely to have absolute and/or relative contraindications to medications commonly used in the management of gouty arthritis, including NSAIDs, corticosteroids, and colchicine. Furthermore, both all-cause and gout-related medical costs for patients with comorbidities and frequent gout were significantly more than those incurred by patients without comorbidities and infrequent gout, or those without comorbidities and frequent gout. Finally, while adjusted all-cause medical costs were not higher for patients with frequent gout, gout-related health-care costs were significantly higher. Thus patients with frequent gout are more difficult and more expensive to treat. We used an updated algorithm to identify gouty arthritis attacks based on available data from medical and prescription claims data sources with the inclusion of the gouty-arthritis attack-specific ICD-9 code 274.01 subsequent to October 2009. In the current study, 45.2% of our entire eligible population with gouty arthritis had at least one gout attack, compared with 35% found by Sarawate and colleagues [16] (mean follow-up time = 29 months) and 40.9% by Wu et al. [17] (12 months of follow-up). However, in addition to methodology differences, the gout population studied by Wu was older (mean age = 72 years) than that of our study (mean age = 58 years) or that of Sarawate and colleagues (mean age = 56 and 58 years for patients with and without attacks, respectively). Primatesta et al. [24] also performed a recent retrospective study and found that among 177 637 gouty arthritis patients (mean age = 55.2 years), 11% of study patients experienced at least one attack during 12 months of follow-up. These retrospective studies have produced a wide range of gouty arthritis attack estimates, and our algorithm appears to have identified more attacks than those used in previously published retrospective claims studies.
One recent retrospective study of refractory gout (patients with 5 3 annual attacks) matched to gout-free controls found that refractory gout patients incurred incremental total health-care costs of $10 222. Furthermore, 40% of these costs were for gout-related health-care costs [15] . We estimated mean total all-cause health-care cost at $10 685 for those with infrequent gout and $10 913 for those with frequent gout, compared with $14 734 for the Wu study population; given the differences in all-cause health-care costs and the older population studied by Wu and colleagues, it is likely that the differences may be explained by both age and comorbidity/disease severity discrepancy in study populations. A 2008 retrospective study estimated that among the 11 935 gouty arthritis patients studied (mean age = 71.4 years), mean unadjusted gout-related health-care costs per patient were $876 in the 12 months following the study index date [13] . These estimates are higher than our study's findings, which estimated annual gout-related health-care costs at $210 for patients with infrequent gout and $889 for those with frequent gout. More recently, Wu and colleagues estimated the mean total health-care cost per gouty arthritis attack among elderly patients studied at $3096, with a mean gout-related cost per attack at $520 [16] .
We found that most patients with either frequent or infrequent gout had absolute and/or relative contraindications to NSAID therapy, although this was higher in patients with frequent gout. Patients with frequent gout are thus more difficult to treat, as they are more likely to have comorbidities that result in absolute and/or relative contraindications to gout medications. Our findings are consistent with earlier findings of Keenan et al., who found that more than 90% of gouty arthritis patients had Costs adjusted to 2011 dollars. P values represent differences for unadjusted cost comparisons via t-test. Adjusted analysis was performed using logarithmic transformation of cost data and generalized linear models with a gamma distribution adjusted for age; chronic condition index; presence of common comorbidities including hypertension, ischaemic heart disease, heart failure, OA, CKD (including hypertensive and diabetic CKD); industry of employment; type of health insurance plan and US geographical region.
at least one contraindication to NSAIDs, in addition to finding high contraindication rates for colchicine, corticosteroids and allopurinol [8] . These investigators also found that gouty arthritis patients were frequently prescribed medications, despite having a contraindication to that medication, and that more than one-third of patients were prescribed colchicine, despite having a strong contraindication. Our study highlights the treatment challenge that a patient with frequent gout presents to prescribers, as for many of these patients, treatment options may be limited and providers may be faced with the choice to either initiate treatment with a gout medication that is not ideal given the patient's other health conditions and medications, or to undertreat the patient for a gouty arthritis attack. Neither of these choices is optimal, and treatment with existing gout medications among patients with absolute and/or relative contraindications may exacerbate existing comorbidities, such as renal disease, hypertension and cardiovascular disease [2528] . Our data reinforce the continued need to improve the overall management of gout. Frequent flares are relatively common in patients with gout [29] , and frequent gout is associated with increased gout-related health-care costs. Moreover, the prevalence of both gout and concurrent comorbidities is increasing [30] . All of these factors increase the clinical complexity and resources need to manage patients with frequent gout. Despite approval of newer agents that prevent gout and manage refractory chronic gout (i.e. febuxostat, pegloticase), new drug therapies (e.g. IL-1 inhibitors, selective urate-anion exchange transporter 1 inhibitors) for the treatment of patients with gout are still needed [31] .
Several limitations of the study are important to consider when interpreting our results. Many variables were unavailable for study inclusion, including the duration of gouty arthritis, patient racial/ethnic background, body mass index, severity of comorbidities and patient alcohol consumption. The list of variables that was used to match frequent to infrequent gout patients was limited to patient age, gender and geographical region; as such, some important differences in patient characteristics between study groups may have remained. However, many of the variables where differences were present were included as covariates in adjusted analyses. We assumed that allopurinol, febuxostat, probenecid or colchicine was prescribed for gout, which cannot account for the infrequent, yet potential use of these agents for other conditions (e.g. colchicine for Familial Mediterranean Fever). Because our study included patients with medical and pharmacy benefit coverage, it may not be representative of the uninsured population. Although our study found that significantly higher gout-related costs were related to attack frequency, all-cause health-care costs were higher among those patients with infrequent gout. This was primarily due to a longer mean length of stay for inpatient hospitalizations among patients with no gouty arthritis attacks and suggests that patients with no yearly attacks may have had more severe comorbidities that resulted in longer hospitalizations.
Conclusions
Gouty arthritis patients who experience frequent gout (53 yearly attacks) may be challenging to treat because they have a higher overall comorbidity burden than patients with infrequent gout. Although there were no differences in adjusted all-cause medical costs in patients with frequent vs infrequent gout, gout-related health-care costs were significantly higher in patients with frequent gout. Rates of all-cause and gout-specific inpatient, outpatient and emergency department utilization were higher in patients with frequent gout compared with those with infrequent gout. Patients with frequent gout are more difficult to treat, as they have high rates of absolute and/or relative contraindications with respect to gouty arthritis medications and higher gout-related treatment costs. Improved treatment options, including those that better manage acute gouty arthritis and reduce attack frequency, are needed in this difficult-to-manage patient population.
Rheumatology key messages
. Frequent gouty arthritis management is complicated by comorbidity and frequent medication absolute and/or relative contraindications to gout therapies. . Frequent gouty arthritis is associated with increased gout-related health-care costs. . Newer and improved therapies are needed for patients with frequent gouty arthritis.
